Australian panel consults on increasing transparency at TGA
This article was originally published in RAJ Devices
The committee that is reviewing the way in which Australia's Therapeutic Goods Administration communicates its regulatory processes and decisions to stakeholders is inviting feedback on how information about the agency's functioning can be better conveyed1.
You may also be interested in...
Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.
EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.